# 3E Bioventures

> 3E Bioventures is a VC fund in Beijing backing Biotechnology and Health Care. See 66 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 66
- Last investment: Jul 2026
- Lead investor: 36%
- Fund size: $200M
- Last fund: Jun 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/3e-bioventures-capital/
- Website: http://www.3ebiovc.com/

3E Bioventures is a VC fund in Beijing focused on Biotechnology and Health Care. 3E Bioventures Capital is a healthcare focused venture investment fund. The core 3E investment team members are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The 3E team combines good global industry perspectives with practical on the ground Chinaexperiences, the team’s past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. 3E Bioventures Capital currently manages both RMB and US Dollar funds, investing in early and growing stage companies in China and overseas. They believe in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years. They aim to leverage their healthcare expertise and experience to ride this historic opportunity, to help build successful healthcare ventures and technologies, to generate good return for their investors, and at the same time, to build 3E Bioventures into a significant international healthcare investment brand.

## Contacts

5 contacts available for 3E Bioventures. Shizune tracks 1 team members at 3E Bioventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/3e-bioventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $6.5M–$50M |
| Series B | $13M–$85M |
| Series C | $29M–$150M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 30 | 45% |
| Health Care | 25 | 38% |
| Medical | 20 | 30% |
| Biopharma | 13 | 20% |
| Therapeutics | 9 | 14% |

31 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 23 | 35% |
| Series B | 16 | 24% |
| Series C | 7 | 11% |
| Angel | 4 | 6% |
| Seed | 3 | 5% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 24 | 36% |
| United States | 21 | 32% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Karen Liu | Founding Partner | 9 | https://shizune.co/investors/profile/karen-liu-f5f3 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tianhu Technology | Tianhu Technology is a computational chemistry and AI-driven innovative drug molecule design provider. |  | Series A | Jul 13, 2026 |  |
| Junhemeng Biopharmaceutical | Junhemeng is a research and development company of recombinant protein drugs. | $29.5M | Series C | Jun 08, 2026 |  |
| Yimou Bio | Yimou Bio focuses on the research and development of small nucleic acid drugs for ophthalmology, aiming to create innovative therapies for the treatment of eye diseases and improve patient outcomes through advanced biotechnology solutions. |  | Angel | May 09, 2026 |  |
| Tianhu Technology | Tianhu Technology is a computational chemistry and AI-driven innovative drug molecule design provider. | $29M | Series A | Mar 16, 2026 |  |
| OncoC4 | OncoC4 is a clinical-stage biotechnology company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer and neurodegenerative disease. | $50M | Series B | Oct 02, 2025 |  |
| Rapafusyn Pharmaceuticals | Rapafusyn Pharmaceuticals licenses technology related to a novel class of natural product-like macrocycle. The company develops novel pharmaceuticals to treat patients having diseases and fulfill other unmet medical needs. | $16M | Series A | Sep 04, 2025 |  |
| Xijian Technology | Xijian Technology is committed to advancing the industrialization of innovative human biomechanics imaging technology. It focuses on health disciplines such as sports rehabilitation, dermatology and beauty, and disease diagnosis and treatment. | $1.4M | Series A | Jul 16, 2025 |  |
| UltraClear | UltraClear is a skincare clinic that provides facial rejuvenation solutions for the treatment of all skin types. | $23M | Series B | May 29, 2025 |  |
| Matwings Technology | Matwings is a biotechnology industry that moves evolution methods to design functionally optimized proteins by leveraging a proprietary. |  | Series A | Nov 15, 2024 |  |
| Tianhu Technology | Tianhu Technology is a computational chemistry and AI-driven innovative drug molecule design provider. | $13.8M | Series A | Nov 15, 2024 |  |

10 of 66 investments shown.

## Co-investors
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 6 deals together
- [CMB International Capital Corporation](https://shizune.co/investors/profile/cmbi-international-capital-corporation) — VC Fund, 4 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 4 deals together
- [Yonjin Venture](https://shizune.co/investors/profile/yonjin-venture) — VC Fund, 4 deals together
- [Gaorong Capital](https://shizune.co/investors/profile/banyan-capital) — VC Fund, 3 deals together
- [Bencao Capital](https://shizune.co/investors/profile/bencao-capital) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in China](https://shizune.co/investors/biotechnology-investors-china)
- [Biotech Investors in China](https://shizune.co/investors/biotech-investors-china)
- [Biotechnology VC Funds in China](https://shizune.co/investors/biotechnology-vc-funds-china)
- [Biotech VC Funds in China](https://shizune.co/investors/biotech-vc-funds-china)
- [Biotech VC Funds in Asia](https://shizune.co/investors/biotech-vc-funds-asia)
- [Medical Investors in China](https://shizune.co/investors/medical-investors-china)

## FAQ

### What does 3E Bioventures invest in?

3E Bioventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 66 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is 3E Bioventures's check size?

3E Bioventures typically joins rounds of $6.5M–$50M at Series A, $13M–$85M at Series B and $29M–$150M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds 3E Bioventures participates in.

### How do I contact 3E Bioventures?

Public channels for 3E Bioventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at 3E Bioventures?

The team at 3E Bioventures includes Karen Liu (Founding Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co